Topical resiquimod promotes priming of CTL to parenteral antigens

Vaccine

Volumn 27, Issue 42, 2009, Pages 5791-5799

  Chang, Brent A ^a   Cross, Jennifer L ^a   Najar, Hossain M ^a   Dutz, Jan P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Skin; TLR; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTIGEN; CHROMIUM; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; OVALBUMIN; PLACEBO; RESIQUIMOD; TETRAMER; TOLL LIKE RECEPTOR AGONIST; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOLOGY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT; SPLEEN CELL; SPLENOMEGALY; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; CROSS-PRIMING; CYTOKINES; FEMALE; IMIDAZOLES; IMMUNITY, CELLULAR; INJECTIONS, SUBCUTANEOUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 69749086126     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.062     Document Type: Article

References (43)

1. Steinman R.M., and Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109 12 (2002) 1519-1526
2. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 (2006) 17-58
3. Tomai M.A., Miller R.L., Lipson K.E., Kieper W.C., Zarraga I.E., and Vasilakos J.P. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 6 5 (2007) 835-847
4. Imbertson L.M., Beaurline J.M., Couture A.M., Gibson S.J., Smith R.M., Miller R.L., et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 110 5 (1998) 734-739
5. Asselin-Paturel C., Brizard G., Chemin K., Boonstra A., O'Garra A., Vicari A., et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201 7 (2005) 1157-1167
6. Johnston D., and Bystryn J.C. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24 11 (2006) 1958-1965
7. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174 5 (2005) 2476-2480
8. Itoh T., and Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28 5 (2005) 430-437
9. Prins R.M., Craft N., Bruhn K.W., Khan-Farooqi H., Koya R.C., Stripecke R., et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176 1 (2006) 157-164
10. Zuber A.K., Brave A., Engstrom G., Zuber B., Ljungberg K., Fredriksson M., et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 22 13-14 (2004) 1791-1798
11. Sauder D.N., Smith M.H., Senta-McMillian T., Soria I., and Meng T.C. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 47 12 (2003) 3846-3852
12. Testerman T.L., Gerster J.F., Imbertson L.M., Reiter M.J., Miller R.L., Gibson S.J., et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58 3 (1995) 365-372
13. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170 8 (2003) 4102-4110
14. Brown D.M., Fisher T.L., Wei C., Frelinger J.G., and Lord E.M. Tumours can act as adjuvants for humoral immunity. Immunology 102 4 (2001) 486-497
15. Carbone F.R., and Bevan M.J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 171 2 (1990) 377-387
16. Najar H.M., and Dutz J.P. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Eur J Immunol 37 8 (2007) 2242-2256
17. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181 1 (1995) 45-54
18. Coles R.M., Mueller S.N., Heath W.R., Carbone F.R., and Brooks A.G. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 168 2 (2002) 834-838
19. Tomai M.A., Gibson S.J., Imbertson L.M., Miller R.L., Myhre P.E., Reiter M.J., et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 28 3 (1995) 253-264
20. Klimuk S.K., Najar H.M., Semple S.C., Aslanian S., and Dutz J.P. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J Invest Dermatol 122 4 (2004) 1042-1049
21. Ahonen C.L., Gibson S.J., Smith R.M., Pederson L.K., Lindh J.M., Tomai M.A., et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 197 1 (1999) 62-72
22. Porgador A., Staats H.F., Faiola B., Gilboa E., and Palker T.J. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 158 2 (1997) 834-841
23. Cheadle E.J., O'Donnell D., Selby P.J., and Jackson A.M. Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 73 2 (2005) 784-794
24. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10 2 (2004) 187-192
25. Kamphuis E., Junt T., Waibler Z., Forster R., and Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108 10 (2006) 3253-3261
26. Baenziger S., Heikenwalder M., Johansen P., Schlaepfer E., Hofer U., Miller R.C., et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113 2 (2009) 377-388
27. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., and Murali-Krishna K. I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202 5 (2005) 637-650
28. Le Bon A., Durand V., Kamphuis E., Thompson C., Bulfone-Paus S., Rossmann C., et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176 8 (2006) 4682-4689
29. Fah J., Pavlovic J., and Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 43 1 (1995) 47-52
30. von Wussow P., Jakschies D., Hochkeppel H.K., Fibich C., Penner L., and Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 20 9 (1990) 2015-2019
31. Broad A., Kirby J.A., and Jones D.E. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. Immunology 120 1 (2007) 103-111
32. Dalpke A.H., Lehner M.D., Hartung T., and Heeg K. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 116 2 (2005) 203-212
33. Dobrovolskaia M.A., Medvedev A.E., Thomas K.E., Cuesta N., Toshchakov V., Ren T., et al. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components. J Immunol 170 1 (2003) 508-519
34. Perry J.A., Olver C.S., Burnett R.C., and Avery A.C. Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J Immunol 174 10 (2005) 5921-5925
35. Shi Y., White D., He L., Miller R.L., and Spaner D.E. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 67 4 (2007) 1823-1831
36. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., and Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 162 4 (1999) 2368-2374
37. Pockros P.J., Guyader D., Patton H., Tong M.J., Wright T., McHutchison J.G., et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47 2 (2007) 174-182
38. Gunzer M., Riemann H., Basoglu Y., Hillmer A., Weishaupt C., Balkow S., et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 106 7 (2005) 2424-2432
39. Krieg A.M., and Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220 (2007) 251-269
40. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174 3 (2005) 1259-1268
41. Wilson N.S., Behrens G.M., Lundie R.J., Smith C.M., Waithman J., Young L., et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 7 2 (2006) 165-172
42. Kuchtey J., Chefalo P.J., Gray R.C., Ramachandra L., and Harding C.V. Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA. J Immunol 175 4 (2005) 2244-2251
43. Tough D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45 2 (2004) 257-264